Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Y Yu

Showing results (91-100 of 234) with videos related to

Pageof 24
Sort By:
Urology|January 14, 2014
Challenges and recommendations for early identification of metastatic disease in prostate cancerE David Crawford, Nelson N Stone, Evan Y Yu, et al.
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
RNA (New York, N.Y.)|March 22, 2003
Lentivirus-delivered stable gene silencing by RNAi in primary cellsSheila A Stewart, Derek M Dykxhoorn, Deborah Palliser, et al.
Cell|July 31, 2003
Telomerase maintains telomere structure in normal human cellsKenkichi Masutomi, Evan Y Yu, Shilagardy Khurts, et al.
Cancer Causes & Control : CCC|January 17, 2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access interventionKristine A Karvonen, Jean A McDougall, Sarah D Hohl, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.
Future Oncology (London, England)|February 24, 2026
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designsEvan Y Yu, Christian Gratzke, Mauricio Burotto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2015
Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687Evan Y Yu, Fenghai Duan, Mark Muzi, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
European Urology Oncology|June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 TrialsMarco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
Pageof 24

Showing results (91-100 of 234) with videos related to

Sort By:
Pageof 24
Urology|January 14, 2014
Challenges and recommendations for early identification of metastatic disease in prostate cancerE David Crawford, Nelson N Stone, Evan Y Yu, et al.
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
RNA (New York, N.Y.)|March 22, 2003
Lentivirus-delivered stable gene silencing by RNAi in primary cellsSheila A Stewart, Derek M Dykxhoorn, Deborah Palliser, et al.
Cell|July 31, 2003
Telomerase maintains telomere structure in normal human cellsKenkichi Masutomi, Evan Y Yu, Shilagardy Khurts, et al.
Cancer Causes & Control : CCC|January 17, 2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access interventionKristine A Karvonen, Jean A McDougall, Sarah D Hohl, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.
Future Oncology (London, England)|February 24, 2026
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designsEvan Y Yu, Christian Gratzke, Mauricio Burotto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 31, 2015
Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687Evan Y Yu, Fenghai Duan, Mark Muzi, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
European Urology Oncology|June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 TrialsMarco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
Pageof 24